CCR4 N-terminal extracellular recombinant protein (N-CCR4-Fc) or C-021 (CCR4 antagonist) can attenuate CCR4+ Tregs-mediated immunosuppression both in vitro and vivo.379 Besides, the H3K27ac and H3K4me1 modification landscapes as well as chromatin accessibility were significantly distinct in tumor-infiltrating Treg cells (TITRs) and peripheral blood Treg cells (PBTRs). This evidence concerns the gene CCR4 and neoplasm.